Last week, artificial intelligence (AI) innovator AION Labs called for applications for its latest AI-powered startups. In partnership with BioMed X, an Israeli company hopes to bring together top talent from around the world to develop an AI platform that can discover new high-affinity small molecules.
Launched in 2021, AION Labs was established in partnership with AstraZeneca, Merck, Pfizer, Teva, Amazon and the Israel Biotechnology Foundation.
Successful startups will be given $1 million in pre-seed funding, access to computational labs and wet labs with cloud support provided by Amazon Web Services, as well as legal and financial assistance from AION to support the company going forward. Business advice is given. This is the 6th time that AION has started recruiting. The startups Omec.AI and DenovaAI launched last year, building on previous rounds focused on other areas of AI-driven drug discovery. Omec.AI identifies hidden safety liability and efficacy gaps in drug candidates, while DenovaAI focuses on novel design of antibodies with strong binding capacity, specifically tailored to epitopes of interest is guessing. Two other team founders from the previous round were also elected.
AION Labs hopes to create a platform that can virtually screen hits from a pre-defined library of small molecules and rank them based on their potential binding affinities. His CTO of AION Labs, Dr. Yair Benita, claimed in a press release that the platform will accelerate the traditionally time-consuming drug discovery process. Drug discovery today relies on accurate information, which is often not available. AI could expedite this process by processing imperfect data, he said, broadening the scope of future research. The company believes this approach has the potential to revolutionize drug discovery in therapeutic areas where mechanisms are unclear or traditional methods have had limited success.
AI has already proven to be a boon in other areas of drug development in recent years, as the COVID-19 pandemic has fueled innovation. GlobalData analysis predicts spending on AI in drug discovery will reach $3.3 billion worth by 2025, more than triple his $1 billion in 2019, up 24.4% year-on-year. % growth.
AI can help meet the demand for open-source research in drug discovery and reduce rising research and development (R&D) costs by leveraging the newly available ultra-large datasets.
CEO Matty Gill praised Israel’s impressive pharmaceutical and technology industries for making these developments possible.he said pharmaceutical technology Israel’s significant healthtech data analytics sector, educated and skilled workforce, renowned universities and medical centers, and government support for the industry have made Israel an attractive destination for pharmaceutical startups. be done.
